Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 3.12
CTIX's Cash to Debt is ranked lower than
67% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. CTIX: 3.12 )
Ranked among companies with meaningful Cash to Debt only.
CTIX' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 2.47 Max: No Debt
Current: 3.12
F-Score: 3
Z-Score: 1.10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -277.69
CTIX's ROE (%) is ranked lower than
95% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. CTIX: -277.69 )
Ranked among companies with meaningful ROE (%) only.
CTIX' s ROE (%) Range Over the Past 10 Years
Min: -319.44  Med: -257.35 Max: -235
Current: -277.69
-319.44
-235
ROA (%) -102.88
CTIX's ROA (%) is ranked lower than
87% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. CTIX: -102.88 )
Ranked among companies with meaningful ROA (%) only.
CTIX' s ROA (%) Range Over the Past 10 Years
Min: -2870.38  Med: -215.36 Max: -99.77
Current: -102.88
-2870.38
-99.77
ROC (Joel Greenblatt) (%) -21963.54
CTIX's ROC (Joel Greenblatt) (%) is ranked lower than
92% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. CTIX: -21963.54 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CTIX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -41215.38  Med: -33618.18 Max: -19765.63
Current: -21963.54
-41215.38
-19765.63
EBITDA Growth (3Y)(%) 46.30
CTIX's EBITDA Growth (3Y)(%) is ranked higher than
90% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CTIX: 46.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CTIX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -5.7  Med: 46.75 Max: 94.9
Current: 46.3
-5.7
94.9
EPS Growth (3Y)(%) 40.10
CTIX's EPS Growth (3Y)(%) is ranked higher than
87% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -4.10 vs. CTIX: 40.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CTIX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 42.15 Max: 100
Current: 40.1
0
100
» CTIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with CTIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:AGTC, NAS:DPRX, NYSE:EVGN, NAS:IMDZ, NAS:GLYC, NAS:PRTO, AMEX:SYN, NAS:CDTX, NAS:NYMX, NAS:ENZY, OTCPK:SIGA, NAS:GNCA, NAS:ATHX, NAS:ADVM, NAS:CDXS, NAS:MDWD, NAS:KURA, NAS:OCUL, NAS:PRQR, NAS:MRUS » details
Cellceutix Corp is a biopharmaceutical company. The Company is engaged in the business of developing small molecule therapies to treat diseases in the areas of cancer and inflammatory disease.

Cellceutix Corporation, formerly known as EconoShare was incorporated on August 1, 2005 in the State of Nevada and was organized for the purpose of developing a B2B website for an Asset Sharing market place and transaction system. On December 6, 2007, EconoShare, Inc. acquired Cellceutix Pharma, Inc., a privately owned Delaware corporation with Cellceutix Pharma becoming a wholly-owned subsidiary of EconoShare, Inc. As a result of the Exchange with Cellceutix Pharma, Inc., the Company has adopted the business plan of Cellceutix Pharma, Inc. and now is into an early stage developmental biopharmaceutical Company. It has acquired rights to seven (7) different pharmaceutical compound candidates that are designed for treatment of diseases which exist, or might exist in the future. The Company would initially spend most of its efforts and resources on its anti-cancer compound, Kevetrin(tm), for the treatment of certain cancers. This compound is furthest along in in-vivo studies in small animals. Based on the results, the Company has decided to advance Kevetrin along the regulatory and clinical pathway. The Company's current portfolio of product candidates in pre-clinical development includes: (i) two (2) anti-cancer agents targeting multiple tumors; (ii) one (1) candidate targeting psoriasis; (iii) one (1) candidate targeting rheumatoid arthritis; (iv) one (1) candidate with potential for indications of osteo-arthritis/asthma; (v) one (1) candidate with a potential for indications of neurological disorders for the treatment of Multiple Sclerosis, Lou Gehrig Disease, and/or Parkinson's Disease; and (vi) a small molecule with potential for development to treat hypertensive emergency. Its product candidate, Kevetrin. Kevetrin is initially being developed to treat certain cancers. The Company is in the business of developing innovative small molecule therapies to treat diseases with significant medical need, particularly in the areas of cancer and inflammatory disease. The Company's compounds are still in preclinical development. It competes with biopharmaceutical firms in the United States, Europe and elsewhere, as well as a growing number of large pharmaceutical companies that are applying biotechnology to its operations. In the United States, drugs are subject to rigorous regulation by the United States Food and Drug Administration ('FDA'). The Federal Food, Drug and Cosmetic Act, and other federal and state statutes and regulations, govern the testing, manufacture, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion of its products.

Ratios

vs
industry
vs
history
P/B 54.58
CTIX's P/B is ranked lower than
97% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. CTIX: 54.58 )
Ranked among companies with meaningful P/B only.
CTIX' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 338.2
Current: 54.58
0
338.2
Current Ratio 0.79
CTIX's Current Ratio is ranked lower than
91% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. CTIX: 0.79 )
Ranked among companies with meaningful Current Ratio only.
CTIX' s Current Ratio Range Over the Past 10 Years
Min: 0.02  Med: 0.58 Max: 2.4
Current: 0.79
0.02
2.4
Quick Ratio 0.79
CTIX's Quick Ratio is ranked lower than
88% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. CTIX: 0.79 )
Ranked among companies with meaningful Quick Ratio only.
CTIX' s Quick Ratio Range Over the Past 10 Years
Min: 0.02  Med: 0.58 Max: 2.4
Current: 0.79
0.02
2.4

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.60
CTIX's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. CTIX: -7.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CTIX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -114.3  Med: -8.15 Max: -0.1
Current: -7.6
-114.3
-0.1

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) -8.00
CTIX's Earnings Yield (Greenblatt) (%) is ranked higher than
52% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. CTIX: -8.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CTIX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -10.45  Med: 0 Max: 0
Current: -8
-10.45
0

More Statistics

EPS (TTM) $ -0.11
Beta1.74
Short Percentage of Float0.00%
52-Week Range $0.94 - 1.96
Shares Outstanding (Mil)124.61
» More Articles for CTIX

Headlines

Articles On GuruFocus.com
Interview with CEO of Cellceutix Corporation: Leo Ehrlich Nov 15 2011 

More From Other Websites
CELLCEUTIX CORP Financials Sep 16 2016
Cellceutix Announces Appointment of Vice President for Regulatory Affairs Sep 16 2016
CELLCEUTIX CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Sep 15 2016
Cellceutix Corporation Provides Business Update and Timeline of Upcoming Milestones Sep 13 2016
CELLCEUTIX CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Sep 13 2016
CELLCEUTIX CORP Files SEC form 10-K, Annual Report Sep 13 2016
Cellceutix Corporation to Present at Upcoming Conferences Sep 07 2016
MP Advisors Issues Research Report on Cellceutix Corporation Sep 01 2016
Cellceutix Further Expands Its Senior Management Team With the Addition of an Industry Veteran Aug 30 2016
With new president and focus on big investors, Cellceutix aims for the Nasdaq Aug 17 2016
They Developed A Disruptive Drug With Government Funding And Trade Crazy Cheap Aug 15 2016
Cellceutix Prepares Phase 2a Ovarian Cancer Trial of Kevetrin, a Novel p53-Modulating Drug... Aug 03 2016
Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis Jul 21 2016
Cellceutix Receives Update on First Patient Enrolled in Phase 2 Proof-of-Concept Study of Brilacidin... Jul 18 2016
CELLCEUTIX CORP Files SEC form 8-K, Regulation FD Disclosure Jul 14 2016
CELLCEUTIX CORP Files SEC form 8-K, Regulation FD Disclosure Jul 08 2016
Cellceutix to Initiate Phase 2b Trial of Prurisol for Chronic Plaque Psoriasis Jul 07 2016
CELLCEUTIX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Jul 01 2016
Cellceutix Corporation Announces Industry Veteran Arthur P. Bertolino, MD, PhD, MBA Joins Company as... Jun 30 2016
Cellceutix Starts Phase 2 Trial of Brilacidin as a Novel Therapy for Ulcerative Proctitis Jun 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)